Roche Diagnostics India appoints Dr Shravan Subramanyam as managing director
A physician from Madras Medical College, Shravan completed his Masters’ degree in Health Administration at Cornell University
Roche Diagnostics India, market leader of the Indian in-vitro diagnostics (IVD) industry, announced the appointment of Dr Shravan Subramanyam as the Managing Director, for its operations in India and the Neighbouring Markets, comprising Bangladesh, Nepal, Sri Lanka and Bhutan.
Guido Sander, who was earlier the Managing Director of Roche Diagnostics India, has shifted base to Singapore, to head High Growth Markets for Roche Diagnostics’ Asia Pacific business. His portfolio, which includes India, now also covers Vietnam, Myanmar, Pakistan and Indonesia.
Speaking about Dr Shravan Subramanyam’s appointment, Sander said, “I am pleased to welcome Dr. Shravan to Roche. His wide experience covering pharmaceuticals and diagnostics, in countries which are at different stages of healthcare evolution will be valuable for the growth plans of the Roche Diagnostics India and Neighbouring Markets business. We are the IVD market leader in India, and are increasingly focusing on enabling patient benefit, through our customers. Dr Shravan’s interest in patient care is synergistic with the organisation’s vision for the future.”
Dr Subramanyam said, “I am excited to be a part of the brand ‘Roche’, which means health and well-being to several lakhs of people across the world. In India, the value that Roche Diagnostics brings to the entire continuum of diagnostics - from screening to diagnosis and monitoring – is very encouraging. I look forward to being a part of this journey, where Roche Diagnostics’ globally renowned solutions are made available in India, to bring patients and their loved ones health and peace of mind.”
A physician from Madras Medical College, Shravan completed his Masters’ degree in Health Administration at Cornell University, where he served on the alumni board. He has a passion for diagnostics, and is particularly keen on exploring “personalized healthcare”, with the goal of “providing the right treatment for the right group of patients.”